Holen Sie sich die Stockscreener-App
5.25
0.77%
0.04
Rezolute Inc Aktie (RZLT) Neueste Nachrichten
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference - The Manila Times
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference -January 31, 2025 at 08:01 am EST - Marketscreener.com
Rare Disease Pioneer Rezolute Takes Center Stage at Elite Guggenheim Biotech Conference - StockTitan
Rezolute receives breakthrough therapy designation for treatment of hypoglycemia - MSN
Cantor Fitzgerald Predicts Rezolute FY2025 Earnings - MarketBeat
Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Average Target Price from Analysts - Defense World
Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Price Target at $24.13 - MarketBeat
Rezolute shares Phase 2 clinical study update By Investing.com - Investing.com South Africa
Rezolute shares Phase 2 clinical study update - Investing.com
Rezolute Highlights Promising Phase 2 Ersodetug Results - TipRanks
(RZLT) On The My Stocks Page - Stock Traders Daily
Top 5 Small-cap Biotech Stocks (Updated January 2025) - Investing News Network
Rezolute, Inc. (NASDAQ:RZLT) Shares Acquired by Geode Capital Management LLC - MarketBeat
Rezolute Gains FDA Breakthrough Designation for Ersodetug - TipRanks
Here's Why 'Trend' Investors Would Love Betting on Rezolute (RZLT) - Yahoo Finance
FDA Grants Breakthrough Therapy Status to Rezolute's Ersodetug for Congenital Hyperinsulinism - StockTitan
State Street Corp Acquires 13,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World
MML Investors Services LLC Makes New $57,000 Investment in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Yahoo Finance
Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Target Price at $24.13 - Defense World
Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Buy" by Analysts - MarketBeat
Rezolute CFO Daron Evans buys $42,900 in company stock By Investing.com - Investing.com Australia
Rezolute CFO Daron Evans buys $42,900 in company stock - Investing.com India
Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 10,000 Shares of Stock - MarketBeat
Rezolute's SWOT analysis: biotech stock's pipeline progress and market potential - Investing.com Nigeria
Rezolute's SWOT analysis: biotech stock's pipeline progress and market potential By Investing.com - Investing.com South Africa
Chief Financial Officer of Rezolute Daron Evans Buys 6.5% More Shares - Simply Wall St
Rezolute (NASDAQ:RZLT) and BetterLife Pharma (OTCMKTS:PVOTF) Head to Head Comparison - Defense World
When the Price of (RZLT) Talks, People Listen - Stock Traders Daily
Rezolute expands authorized shares following shareholder approval - Investing.com
Daron Evans, CFO of Rezolute, buys $53,166 in common shares By Investing.com - Investing.com Nigeria
Daron Evans, CFO of Rezolute, buys $53,166 in common shares - Investing.com
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug - MSN
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Rezolute Grants 150,000-Share Inducement Award to New Supply Chain Executive - StockTitan
Rezolute retains steady stock target on Orphan Drug nod By Investing.com - Investing.com Canada
RZLT Stock Rises On FDA's Orphan Designation For Rare Disease Drug - Barchart
FDA Grants Orphan Drug Designation to Rezolute's Ersodetug for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - Marketscreener.com
Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market (NASDAQ:RZLT) - Seeking Alpha
Rezolute Receives Orphan-Drug Designation from FDA for Low Blood Sugar Treatment - MarketWatch
FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - The Manila Times
Rezolute's Hypoglycemia Drug Wins FDA Orphan Drug Status; Phase 3 Trial Set for 2025 - StockTitan
Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Average Price Target from Analysts - MarketBeat
Rezolute, Inc. Advances Late-Stage Trials for Rare Disease Therapies - TipRanks
BTIG Initiates Coverage of Rezolute (RZLT) with Buy Recommendation - MSN
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):